Cargando…
918. Typhoid Fever in the US Pediatric Population, 1999–2015, and the Potential Benefits of New Vaccines
BACKGROUND: In the United States, typhoid fever is rare. About 300 typhoid cases are reported to CDC annually through the National Typhoid and Paratyphoid Fever Surveillance (NTPFS) system. Most are acquired during international travel and while visiting friends and relatives. CDC recommends pretrav...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252716/ http://dx.doi.org/10.1093/ofid/ofy209.059 |
_version_ | 1783373327891431424 |
---|---|
author | McAteer, Jarred Derado, Gordana Hughes, Michael Bhatnagar, Amelia Medalla, Felicita Chatham-Stephens, Kevin Appiah, Grace D Mintz, Eric D |
author_facet | McAteer, Jarred Derado, Gordana Hughes, Michael Bhatnagar, Amelia Medalla, Felicita Chatham-Stephens, Kevin Appiah, Grace D Mintz, Eric D |
author_sort | McAteer, Jarred |
collection | PubMed |
description | BACKGROUND: In the United States, typhoid fever is rare. About 300 typhoid cases are reported to CDC annually through the National Typhoid and Paratyphoid Fever Surveillance (NTPFS) system. Most are acquired during international travel and while visiting friends and relatives. CDC recommends pretravel vaccination of at-risk children with one of two currently available vaccines: oral (age ≥6 years) or injectable (age ≥2 years). In anticipation of licensure of new protein-conjugate typhoid vaccines that could be administered to children ≥6 months old, we characterized clinical, epidemiologic, and antimicrobial resistance data of pediatric typhoid fever cases reported to CDC. METHODS: We reviewed laboratory-confirmed Salmonella enterica serotype Typhi infections reported to NTPFS and antimicrobial resistance data on Typhi isolates in the National Antimicrobial Resistance Monitoring System (NARMS) from 1999 to 2015. RESULTS: Of 2,051 pediatric (≤18 years) cases of typhoid fever, 80% had traveled internationally within 30 days of illness onset (most frequently to South Asia [82%]), 81% were hospitalized (median duration 6 days; range 0–77 days), and none died. Eight hundred twenty-seven (40%) were <6 years old; 219 (26%) were 6 months–2 years old. While 76% of pediatric cases were vaccine eligible (travelers ≥2 years old), only 6% were known to be vaccinated. Of 2,020 isolates tested for antimicrobial susceptibility, 1,211 (60%) had decreased susceptibility or resistance to ciprofloxacin, of which 277 (23%) were also resistant to ampicillin, chloramphenicol, and trimethoprim/sulfamethoxazole (multidrug-resistant [MDR]). None were resistant to ceftriaxone or azithromycin. MDR isolates were more likely in children than adults (16% vs. 9%, P < 0.05) and in travel-associated than domestically acquired cases (16% vs. 6%, P < 0.05). CONCLUSION: Among pediatric cases of typhoid fever, 94% of currently vaccine-eligible travelers were unvaccinated. Emphasis on current vaccine indications and an effective pretravel typhoid vaccine for children between 6 months and 2 years old available during routine immunization visits could begin to reduce the burden of disease, and help prevent drug-resistant infections, in this vulnerable age group. [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6252716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62527162018-11-28 918. Typhoid Fever in the US Pediatric Population, 1999–2015, and the Potential Benefits of New Vaccines McAteer, Jarred Derado, Gordana Hughes, Michael Bhatnagar, Amelia Medalla, Felicita Chatham-Stephens, Kevin Appiah, Grace D Mintz, Eric D Open Forum Infect Dis Abstracts BACKGROUND: In the United States, typhoid fever is rare. About 300 typhoid cases are reported to CDC annually through the National Typhoid and Paratyphoid Fever Surveillance (NTPFS) system. Most are acquired during international travel and while visiting friends and relatives. CDC recommends pretravel vaccination of at-risk children with one of two currently available vaccines: oral (age ≥6 years) or injectable (age ≥2 years). In anticipation of licensure of new protein-conjugate typhoid vaccines that could be administered to children ≥6 months old, we characterized clinical, epidemiologic, and antimicrobial resistance data of pediatric typhoid fever cases reported to CDC. METHODS: We reviewed laboratory-confirmed Salmonella enterica serotype Typhi infections reported to NTPFS and antimicrobial resistance data on Typhi isolates in the National Antimicrobial Resistance Monitoring System (NARMS) from 1999 to 2015. RESULTS: Of 2,051 pediatric (≤18 years) cases of typhoid fever, 80% had traveled internationally within 30 days of illness onset (most frequently to South Asia [82%]), 81% were hospitalized (median duration 6 days; range 0–77 days), and none died. Eight hundred twenty-seven (40%) were <6 years old; 219 (26%) were 6 months–2 years old. While 76% of pediatric cases were vaccine eligible (travelers ≥2 years old), only 6% were known to be vaccinated. Of 2,020 isolates tested for antimicrobial susceptibility, 1,211 (60%) had decreased susceptibility or resistance to ciprofloxacin, of which 277 (23%) were also resistant to ampicillin, chloramphenicol, and trimethoprim/sulfamethoxazole (multidrug-resistant [MDR]). None were resistant to ceftriaxone or azithromycin. MDR isolates were more likely in children than adults (16% vs. 9%, P < 0.05) and in travel-associated than domestically acquired cases (16% vs. 6%, P < 0.05). CONCLUSION: Among pediatric cases of typhoid fever, 94% of currently vaccine-eligible travelers were unvaccinated. Emphasis on current vaccine indications and an effective pretravel typhoid vaccine for children between 6 months and 2 years old available during routine immunization visits could begin to reduce the burden of disease, and help prevent drug-resistant infections, in this vulnerable age group. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6252716/ http://dx.doi.org/10.1093/ofid/ofy209.059 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts McAteer, Jarred Derado, Gordana Hughes, Michael Bhatnagar, Amelia Medalla, Felicita Chatham-Stephens, Kevin Appiah, Grace D Mintz, Eric D 918. Typhoid Fever in the US Pediatric Population, 1999–2015, and the Potential Benefits of New Vaccines |
title | 918. Typhoid Fever in the US Pediatric Population, 1999–2015, and the Potential Benefits of New Vaccines |
title_full | 918. Typhoid Fever in the US Pediatric Population, 1999–2015, and the Potential Benefits of New Vaccines |
title_fullStr | 918. Typhoid Fever in the US Pediatric Population, 1999–2015, and the Potential Benefits of New Vaccines |
title_full_unstemmed | 918. Typhoid Fever in the US Pediatric Population, 1999–2015, and the Potential Benefits of New Vaccines |
title_short | 918. Typhoid Fever in the US Pediatric Population, 1999–2015, and the Potential Benefits of New Vaccines |
title_sort | 918. typhoid fever in the us pediatric population, 1999–2015, and the potential benefits of new vaccines |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252716/ http://dx.doi.org/10.1093/ofid/ofy209.059 |
work_keys_str_mv | AT mcateerjarred 918typhoidfeverintheuspediatricpopulation19992015andthepotentialbenefitsofnewvaccines AT deradogordana 918typhoidfeverintheuspediatricpopulation19992015andthepotentialbenefitsofnewvaccines AT hughesmichael 918typhoidfeverintheuspediatricpopulation19992015andthepotentialbenefitsofnewvaccines AT bhatnagaramelia 918typhoidfeverintheuspediatricpopulation19992015andthepotentialbenefitsofnewvaccines AT medallafelicita 918typhoidfeverintheuspediatricpopulation19992015andthepotentialbenefitsofnewvaccines AT chathamstephenskevin 918typhoidfeverintheuspediatricpopulation19992015andthepotentialbenefitsofnewvaccines AT appiahgraced 918typhoidfeverintheuspediatricpopulation19992015andthepotentialbenefitsofnewvaccines AT mintzericd 918typhoidfeverintheuspediatricpopulation19992015andthepotentialbenefitsofnewvaccines |